News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
691,144 Results
Type
Article (41468)
Company Profile (332)
Press Release (649344)
Section
Business (207553)
Career Advice (1992)
Deals (35920)
Drug Delivery (81)
Drug Development (83000)
Employer Resources (168)
FDA (16193)
Job Trends (15029)
News (350562)
Policy (32966)
Tag
Academia (2626)
Africa (730)
Alabama (32)
Allergies (38)
Alliances (50436)
Alzheimer's disease (1135)
Antibody-drug conjugate (ADC) (49)
Approvals (16133)
Arizona (167)
Artificial intelligence (52)
Asia (38030)
Australia (6309)
Bankruptcy (359)
Best Places to Work (11395)
Biosimilars (56)
C2C Services and Suppliers (79837)
California (830)
Canada (643)
Cancer (187)
Career advice (1664)
CAR-T (36)
Cell therapy (73)
China (49)
Clinical research (64361)
Collaboration (63)
Colorado (35)
COVID-19 (2514)
Cystic fibrosis (73)
Diabetes (34)
Diagnostics (5953)
Diversity, equity & inclusion (44)
Drug pricing (54)
Earnings (83997)
Employer resources (142)
Europe (82848)
Events (110387)
FDA (16236)
Florida (106)
Funding (40)
Gene therapy (61)
GLP-1 (496)
Government (4361)
Healthcare (18922)
Hotbed/Location (488857)
Idaho (56)
Illinois (202)
Indiana (107)
Infectious disease (2527)
Inflammatory bowel disease (89)
Interviews (315)
IPO (16392)
Job creations (3691)
Job search strategy (1435)
Kansas (92)
Layoffs (398)
Legal (7893)
Liver cancer (52)
Lung cancer (40)
Maine (47)
Management (53)
Manufacturing (46)
Maryland (257)
Massachusetts (456)
Medical device (13120)
Medtech (13123)
Mergers & acquisitions (19219)
Metabolic disorders (169)
Neuroscience (1217)
New Jersey (62)
New York (84)
NextGen Class of 2024 (6700)
Non-profit (4524)
North Carolina (167)
Obesity (110)
Opinion (178)
Patents (33)
Peanut (34)
Pennsylvania (56)
People (56933)
Phase I (20127)
Phase II (28406)
Phase III (21072)
Podcasts (33)
Policy (36)
Postmarket research (2590)
Preclinical (8660)
Rare diseases (94)
Real estate (5993)
Recruiting (64)
Regulatory (21459)
Reports (32)
Research institute (2393)
Resumes & cover letters (348)
South America (1104)
Startups (3737)
Texas (87)
United States (3065)
Vaccines (422)
Washington State (114)
Weight loss (107)
Date
Today (45)
Last 7 days (504)
Last 30 days (1950)
Last 365 days (39394)
2024 (22321)
2023 (41047)
2022 (52302)
2021 (56804)
2020 (54994)
2019 (47552)
2018 (35813)
2017 (33090)
2016 (32442)
2015 (38491)
2014 (32267)
2013 (27194)
2012 (29306)
2011 (29949)
2010 (28069)
691,144 Results for "intensity therapeutics inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
Intensity Therapeutics, Inc. Announces the Appointment of Thomas Dubin to Its Board of Directors
Intensity Therapeutics, Inc. announces the appointment of Thomas Dubin, J.D., MPH, to the Intensity Board of Directors, effective May 14, 2024.
May 15, 2024
·
6 min read
Business
Intensity Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
Intensity Therapeutics, Inc. (“Intensity” or “the Company”) (Nasdaq: INTS) announces first quarter 2024 financial results and provides a corporate update.
May 9, 2024
·
9 min read
Drug Development
Intensity Therapeutics, Inc. & The Swiss Group for Clinical Cancer Research SAKK Sign a Collaboration Agreement to Conduct a Phase 2 Randomized, Clinical Trial in Early-Stage Breast Cancer in Europe for INT230-6, Intensity’s Lead Drug Candidate
Intensity Therapeutics, Inc. announces that the Company executed a collaboration agreement with The Swiss Group for Clinical Cancer Research SAKK to conduct a Phase 2 randomized, controlled trial evaluating clinical and biological effects of intratumoral INT230-6 followed by the standard of care immuno/chemotherapy vs. SOC immune/chemotherapy alone in early-stage triple-negative breast cancer in 54 patients in Switzerland and selected countries in Europe.
May 10, 2024
·
8 min read
Pharm Country
Portage Biotech Completes Monetization of Intensity Therapeutics (INTS) shares
Portage Biotech Inc. reported that it has completed selling its equity holding in Intensity Therapeutics.
March 26, 2024
·
3 min read
Pharm Country
Intensity Therapeutics Reports Full Year 2023 Financial Results and Provides Corporate Update
Intensity Therapeutics, Inc. (“Intensity” or “the Company”) (Nasdaq: INTS) announces full year 2023 financial results and provides a review of 2023 accomplishments and anticipated upcoming developments.
March 14, 2024
·
11 min read
News
Intensity Therapeutics, Inc. Announces First Patient Dosed in its Global Randomized, Phase 3 Study
July 9, 2024
·
7 min read
Pharm Country
Intensity Therapeutics to Participate in the LD Micro Invitational XIV Conference April 8 - 9, 2024
Intensity Therapeutics, Inc. (Nasdaq: INTS) announces that Lewis H. Bender, Founder, President and Chief Executive Officer, will present a corporate overview at the LD Micro Invitational XIV 2024.
April 2, 2024
·
3 min read
Drug Development
Our Mission at Voyager Therapeutics: Define the Future of Neurogenetic Medicines
We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system
May 8, 2024
·
3 min read
·
Voyager Therapeutics, Inc.
Pharm Country
Intensity Therapeutics to Present at the 2024 BIO CEO & Investor Conference
Intensity Therapeutics, Inc. today announced that Lewis H. Bender, President and Chief Executive Officer, will present a company overview at the 2024 BIO CEO & Investor Conference on Monday, February 26, 2024, at the New York Marriott Marquis at 11:45am ET in the Uris Room.
February 21, 2024
·
3 min read
Pharm Country
Intensity Therapeutics to Participate in the 36th Annual Roth Conference March 17 to 19, 2024
Intensity Therapeutics, Inc. announces that Lewis H. Bender , Founder, President will participate in a fireside chat with Roth Managing Director and Senior Analyst, Jonathan Aschoff, Ph.D. at the 36th Annual Roth Conference in Orange County, CA on Tuesday, March 19, at 12:30PM PDT.
March 14, 2024
·
3 min read
1 of 69,115
Next